Last one to leave please shut off the lights, bond holders are about to own a mess of Texas acreage, zaza bankruptcy is in play...
Remember while oil prices drop, nearly 1/2 of zaza's production is natural gas which has held steady. I agree with either a buyout or major joint venture plays in the works. Also should have some news on refinancing the debt soon.
Raymond James guy just called bottom in oil stocks just now on cnbc, Zaza gets taken out soon, someone keeps hitting the bid all morning, naked shorts will get killed in this little stock
I think Zaza is doing all of this settling of agreements because they are getting ready to take an offer for the company.
In conclusion, these factors scratch the surface of how MiMedx is starting to climb its way to being the leader in biological wound care, just as Petit has done with a number of companies before this. Institutional awareness has been jolted awake after the open demonstration and inclusion into the company's developments on Analyst Day. Despite the recent pop in the few days following the Analyst Day, MDXG has still yet to regain yearly highs, so the upside potential and growth story are very largely intact. Considering that the wound market is only one part of the company's portfolio; with surgical, orthopedics and sports medicine as further drivers of growth, Petit's own metric for valuation being 10x 2015 revenue seems fair. Using that metric puts the stock at a sweet spot around $16.50, or a cool 100% upside to current prices. I would say that would be a very nice first step for investors as we join MDXG in its climb to the top.
Current treatments using dermal grafts already exist in the forms of Apligraf® and Dermagrafts, the former being derived from living cells, and the latter being a scaffold of human fibroblasts. Both of these current treatments work by providing a matrix to attract epithelial and skin cells close to the wound in order to close it. In a retrospective study by MiMedx comparing EpiFix® to Apligraf® and Dermagraft (see here), the superiority of EpiFix® is surprisingly clear. For Apligraf® and Dermagraft, the rates of complete healing are low (92% EpiFix® vs. 56% and 30% for Apligraf® and Dermagraft , respectively), the time it takes to get to that healing is extensive (12 weeks vs. 2-6 weeks for EpiFix), and the cost per patient is rather sizable ($3,091 vs. $7097 vs. $11,881, respectively).
In addition to these differences, Apligraft® and Dermagraft require special handling and shipping requirements, need to be frozen for storage and then thawed making them difficult to use, and limited sizes of the grafts on the larger side, results in a high percentage of waste these products produce. The underlying reason for why MiMedx has such a superior product is that they have been able to process these placental tissues in a number of optimizing ways that are patent protected that other competitors cannot or will not be able to replicate.
First, they are able to maintain the structural integrity of the multiple amnion and chorion layers during separation (See Figure 1). Second, they dehydrate the tissue allowing it to preserve almost all of the growth factors present (See Figure 2). Lastly, the dehydrated, active forms of these grafts can be stored at room temperature for up to five years versus needing to be constantly refrigerated or frozen. For a striking study directly comparing the differences between multi-layer grafts versus a would-be competitor's single-layer graft
Epifix doesn't use any human embryonic stem cells. It acts as a stem cell magnet to let your body use it's own stem cells for healing. That is the huge advantage over OSIR as it's frozen living cells dies with out acting as a stem cell magnet.
That has to be the most stupid question asked in years on this board. You are obviously short or you did zero research before opening your mouth, either way we have this great tool that just came out called the internet, go do your homework please..
Not a good sign when a former comptroller dumps 100 percent of his OSIR holding. Either sour grapes or he knows something. Chart looks like this is going to single digits soon, I will buy some then. Until then, volume is pathetic.
Because some idiot put in a market order for 1000 shares to a thinly traded stock that no one cares about but us, then said thank you very much.
Sorry, didn't hear the sarcasm , my bad, but as you can tell, I am an upset libertarian.
Hopefully all of the analyst participated in the secondary. If you have any understanding of how Wallstreet and capitalism are mixed with Greed, then welcome to America. Sounds like you want to live in a Marxist, liberal society. If that is what you want, please go visit your local dmv or post office, that is what all businesses will look like if the liberal agenda of dividing our country continues. Of course the following analyst will participate in the secondary, you must not have been trading for many years to make an ignorant claim such as that.
Don't be so sensitive about the thumbs down, it was me but I actually tried to give a thumbs up but on my ipad the button is small and I missed, so a verbal thumbs up, sorry.
Hair regrowth has been mentioned on this board with links. I don't have them in front of me but they are out on the web with some nasty hair surgery pics using amniofix.
Amniofix injectable will replace both procedures, and already is in some clinics. Mdxg will be a 100 dollar stock, unfortunately it will be bought out soon for 30 bucks so we will never see 100. Goodbye shorts...and just for good measure, if your tendons feel better after an injection of amniofix, rub a little on your scalp and grow back that mop, wonder drug and fountain of youth.
Don't care about dsci, high end skin not apples to apples,,,for mdxg I predict this is the earnings announcement when the buy out offers appear, deal in 2015 for 23 bucks a share.
You really are an idiot for a headline that says Taylor sells. Much like a one sided liberal media outlet you failed to mention he exercised options and converted those with the sale of some of his common. So if you were not an idiot, you would note that he increased his holdings, idiot...
Cnbc headlining biotech plunging, code for bottom is in, now is the time to buy the good names